Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,554,146
  • Shares Outstanding, K 149,765
  • Annual Sales, $ 8,250 K
  • Annual Income, $ -448,720 K
  • 60-Month Beta 0.74
  • Price/Sales 881.81
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BBIO with:

Options Overview Details

View History
  • Implied Volatility 59.00%
  • Historical Volatility 41.77%
  • IV Percentile 61%
  • IV Rank 32.75%
  • IV High 86.68% on 02/17/21
  • IV Low 45.53% on 12/10/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 253
  • Volume Avg (30-Day) 158
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 76
  • Open Int (30-Day) 104

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.88
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -1.10
  • Prior Year -0.98
  • Growth Rate Est. (year over year) +10.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.10 +7.62%
on 09/16/21
52.38 -3.24%
on 09/08/21
+0.21 (+0.42%)
since 08/27/21
3-Month
46.68 +8.59%
on 08/20/21
65.33 -22.41%
on 07/07/21
-8.70 (-14.65%)
since 06/28/21
52-Week
36.20 +40.04%
on 10/05/20
73.50 -31.03%
on 02/09/21
+13.85 (+37.60%)
since 09/28/20

Most Recent Stories

More News
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.08 (-0.71%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.08 (-0.71%)
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first...

BBIO : 50.08 (-0.71%)
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

AIG : 55.98 (-1.84%)
BBIO : 50.08 (-0.71%)
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 29.03% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 50.08 (-0.71%)
BridgeBio Pharma: Q2 Earnings Snapshot

PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $96.3 million in its second quarter.

BBIO : 50.08 (-0.71%)
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients...

BBIO : 50.08 (-0.71%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.08 (-0.71%)
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic...

BBIO : 50.08 (-0.71%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.08 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 54.14
2nd Resistance Point 52.43
1st Resistance Point 51.44
Last Price 50.08
1st Support Level 48.74
2nd Support Level 47.03
3rd Support Level 46.04

See More

52-Week High 73.50
Fibonacci 61.8% 59.25
Fibonacci 50% 54.85
Fibonacci 38.2% 50.45
Last Price 50.08
52-Week Low 36.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar